-
Factor Xa: Fights Atherosclerosis
Time of Update: 2022-02-19
The team's new study shows that administering a sufficient dose of rivaroxaban (RIV) inhibits the activity of factor Xa and effectively reduces areas of atherosclerosis in mice .
-
Read the whole article!
Time of Update: 2022-02-19
In the long run, such chimeras could be used to study early human development, develop disease models, screen for potential new drugs, and create cells, tissues or organs that can be transplanted to rescue patients who need transplants .
-
100% disease control rate in patients with pancreatic and gastrointestinal cancers with positive KRAS inhibitor Phase 2 results
Time of Update: 2022-02-19
In a cohort of previously treated patients with pancreatic ductal adenocarcinoma and other gastrointestinal (GI) cancers harboring a KRAS G12C mutation, adagrasib demonstrated significant clinical activity and broad disease control .
References:[1] Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers.
-
New software may help neuropathic patients access clinical data on their own smartphones
Time of Update: 2022-02-19
The new study, led by Hopkins, sought to find out whether pose estimation software developed by the research team could track human movements as accurately as manual, frame-by-frame visual inspections of video recordings of patients' movements .
-
Cell Death and Differentiation: A New Mechanism of Programmed Cell Necrosis and Regulation of Immune Homeostasis
Time of Update: 2022-02-19
On January 21, 2022, Zhang Haibing's research group from Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences published online in the international academic journal Cell Death and Differentiation entitled "Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to "prevent lymphopenia" research results .
-
SLAMF3 and SLAMF4 are immune checkpoints that limit phagocytosis of hematopoietic tumor macrophages
Time of Update: 2022-02-19
Here, we report the essential role of SLAM family receptors (SFRs), which are widely expressed in hematopoietic cells and form homotypic interactions, in the inhibition of macrophage phagocytosis .
-
Bristol-Myers Squibb's 'first-in-class' anemia treatment expected to be approved in China soon
Time of Update: 2022-02-19
In February 2021, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration accepted the marketing application of rotacept for injection and included it in priority review as a "conditionally approved drug" for treatment Adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions .
-
Early-onset cancer rates are on the rise, and why?
Time of Update: 2022-02-19
Professor Claire Roberts, co-lead author of the study, said men between the ages of 18 and 50 had a 1 per cent increased chance of developing these cancers each year .
-
CDK4/6: New insights into old targets
Time of Update: 2022-02-19
▲ The mechanism by which CDK4/6 regulates cell cycle progression (Image source: Reference [1])Three of the inhibitors developed based on inhibition of CDK/6 activity have been approved by the US FDA for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, including Pfizer's palbociclib, Novartis' ribociclib and Eli Lilly's abemaciclib .
-
An Oral Supplement May Boost Muscle and Mitochondrial Health
Time of Update: 2022-02-19
New research suggests that this supplement, urolithin A, may help improve or prolong muscle activity in older adults or people with medical conditions that make exercise difficult .
-
Parthenogenetic ticks promote rapid spread of fever with thrombocytopenia syndrome virus
Time of Update: 2022-02-19
The parthenogenetic population of Haemophilus longhorn was discovered in New Jersey in 2017 , and has spread to 12 states in the central and eastern United States by 2020 , further confirming this theory .
-
Details of Omicron's infection of human cells revealed
Time of Update: 2022-02-19
Science and Technology Daily, Beijing, January 23 (Reporter Liu Xia) According to a report by the Physicist Organization Network on the 20th, researchers from the University of British Columbia School
-
When children have febrile seizures, genes are involved
Time of Update: 2022-02-19
Researchers from the iPSYCH psychiatry programme in Denmark have been involved in a major international study and have discovered new genes that increase the risk of febrile seizures .
-
ACE2 receptor protein "nanobubbles" can prevent new crowns
Time of Update: 2022-02-19
Science and Technology Daily, Beijing, January 23 (Intern reporter Zhang Jiaxin) According to a paper published in the journal "Nature Communications" on the 20th, scientists from Northwestern Univers
-
A new treatment for amyotrophic lateral sclerosis: silencing FUS expression by antisense oligonucleotides
Time of Update: 2022-02-19
In a FUSP525L-mutated ALS patient, we provide preliminary evidence that repeated intrathecal infusions of ION363 reduced CNS levels of wild-type and mutant FUS, resulting in a significant reduction in the burden of FUS aggregation, a pathological hallmark of the disease .
-
Wu Hong's group from the School of Life Sciences Reveals a New Mechanism of Converting "Cold" Tumors to "Hot" Tumors to Promote Prostate Cancer Immunotherapy
Time of Update: 2022-02-19
In the latest study, Wu Hong's group further found that intermittent administration of BAY1082439 could up-regulate cancer cell antigen presentation and T-cell chemokine expression by inhibiting the PI3K-regulated immunosuppressive pathway, and reduce T-regulatory cell-mediated tumorigenesis.
-
The Lancet: Oral immunotherapy reduces peanut allergy in some young children
Time of Update: 2022-02-19
After avoiding peanuts for six months after treatment, 21% of the children who received peanut flour received 5 grams of peanut protein during the second oral food challenge without experiencing an allergic reaction and thus were in remission .
-
Look at the GMP development process of cell therapy products
Time of Update: 2022-02-19
06, the General Department of the State Food and Drug Administration publicly solicited opinions on the "Good Manufacturing Practice for Drugs - Cell Therapy Product Addendum (Draft for Comment)".
-
New drug for lung cancer: disease control rate as high as 92%
Time of Update: 2022-02-18
Experimental research, the results show [3]:• The objective response rate of non-small cell lung cancer patients can reach 55.
6%• The objective response rate of 11 patients with HER2-mutated non-small cell lung cancer was as high as 72.
-
PLOS Digital Health: AI identifies individuals at risk for heart disease complications
Time of Update: 2022-02-18
"We can bring artificial intelligence to help refine the risk of virtually any medical diagnosis," said Martin Tristani-Firouzi, corresponding author of the medical study and a pediatric cardiologist at U of Health and Intermountain Children's Hospital, Nora and scientist Ike Harrison Cardiovascular Research and Training Institute .
